MA54095A - Formulations pharmaceutiques aqueuses - Google Patents

Formulations pharmaceutiques aqueuses

Info

Publication number
MA54095A
MA54095A MA054095A MA54095A MA54095A MA 54095 A MA54095 A MA 54095A MA 054095 A MA054095 A MA 054095A MA 54095 A MA54095 A MA 54095A MA 54095 A MA54095 A MA 54095A
Authority
MA
Morocco
Prior art keywords
pharmaceutical formulations
aqueous pharmaceutical
aqueous
formulations
pharmaceutical
Prior art date
Application number
MA054095A
Other languages
English (en)
Inventor
Wen-Cheng Chang
Jiung-Liang Liu
Jheng-Gang Yang
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MA54095A publication Critical patent/MA54095A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA054095A 2018-10-31 2019-10-24 Formulations pharmaceutiques aqueuses MA54095A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862753084P 2018-10-31 2018-10-31

Publications (1)

Publication Number Publication Date
MA54095A true MA54095A (fr) 2022-02-09

Family

ID=70463495

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054095A MA54095A (fr) 2018-10-31 2019-10-24 Formulations pharmaceutiques aqueuses

Country Status (12)

Country Link
US (1) US12433948B2 (fr)
EP (1) EP3873437A4 (fr)
JP (2) JP7411652B2 (fr)
KR (1) KR102917813B1 (fr)
AU (1) AU2019372568B2 (fr)
BR (1) BR112021008155A2 (fr)
CA (1) CA3117245A1 (fr)
IL (1) IL282343A (fr)
MA (1) MA54095A (fr)
MX (1) MX2021005015A (fr)
NZ (1) NZ775236A (fr)
WO (1) WO2020088346A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7411652B2 (ja) * 2018-10-31 2024-01-11 リヒター ゲデオン ニュイルヴァーノシャン ミューコェデー レースヴェーニュタールシャシャーグ 水性医薬製剤
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
WO2021228917A1 (fr) * 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prévention de la formation de particules visibles dans des solutions de protéines parentérales

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI505838B (zh) * 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
EP2638067A2 (fr) * 2010-11-08 2013-09-18 Genentech, Inc. Anticorps anti-récepteur de l'il-6 administré par voie sous-cutanée
CA3012350A1 (fr) 2016-02-23 2017-08-31 Sesen Bio, Inc. Formulations d'antagonistes d'il-6 et leurs utilisations
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
EP3964197A1 (fr) 2016-10-31 2022-03-09 Fresenius Kabi Deutschland GmbH Composition pharmaceutique liquide
CN107760760A (zh) * 2017-09-28 2018-03-06 中国食品药品检定研究院 一种快速测定il‑6/il‑6受体抗体药物生物学活性的方法
JP7411652B2 (ja) 2018-10-31 2024-01-11 リヒター ゲデオン ニュイルヴァーノシャン ミューコェデー レースヴェーニュタールシャシャーグ 水性医薬製剤

Also Published As

Publication number Publication date
WO2020088346A1 (fr) 2020-05-07
KR102917813B1 (ko) 2026-01-26
AU2019372568A1 (en) 2021-05-20
KR20210094552A (ko) 2021-07-29
US20210393783A1 (en) 2021-12-23
MX2021005015A (es) 2021-07-21
CA3117245A1 (fr) 2020-05-07
NZ775236A (en) 2025-10-31
EP3873437A1 (fr) 2021-09-08
JP7730882B2 (ja) 2025-08-28
IL282343A (en) 2021-05-31
JP2024041791A (ja) 2024-03-27
BR112021008155A2 (pt) 2021-08-10
AU2019372568B2 (en) 2025-01-30
JP2022506042A (ja) 2022-01-17
EP3873437A4 (fr) 2022-08-03
US12433948B2 (en) 2025-10-07
JP7411652B2 (ja) 2024-01-11

Similar Documents

Publication Publication Date Title
MA52421A (fr) Composés pharmaceutiques
EP4045480A4 (fr) Formulations pharmaceutiques
MA50541A (fr) Formulations pharmaceutiques
EP3541385A4 (fr) Formulations pharmaceutiques
EP3638248A4 (fr) Conjugués de principes pharmaceutiques actifs
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
MA42303A (fr) Formulations pharmaceutiques
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
MA55015A (fr) Formulations pharmaceutiques
EP3761961A4 (fr) Formulations aqueuses pour médicaments insolubles
DK3634377T3 (da) Farmaceutisk formulering
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
EP3463345A4 (fr) Combinaisons pharmaceutiques
EP3603642A4 (fr) Préparation pharmaceutique
DK4233850T3 (da) Kapselformuleringer
IL283900A (en) Pharmaceutical combinations
EP3454847A4 (fr) Formulations de médicaments améliorées
MA49837A (fr) Compositions pharmaceutiques
EP3646866A4 (fr) Préparation pharmaceutique
EP3337463A4 (fr) Formulations pharmaceutiques
MA54095A (fr) Formulations pharmaceutiques aqueuses
EP3746080A4 (fr) Formulations pharmaceutiques
HUE069648T2 (hu) Gyógyszerészeti készítmény
DK3601277T3 (da) Farmaceutisk formulering
EP3630074C0 (fr) Forme posologique orale multiparticulaire à libération prolongée de tapentadol